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Abstract
The gastrointestinal tract harbors a large number and 
diverse array of commensal bacteria and is an impor-
tant entry site for pathogens. For these reasons, the 
intestinal immune system is uniquely dedicated to pro-
tect against infections, while avoiding the development 
of destructive inflammatory responses to the micro-
biota. Several models have been proposed to explain 
how the immune system discriminates between, and 
appropriately responds to, commensal and pathogenic 
microorganisms. Dendritic cells (DCs) and regulatory 
T cells (Treg) are instrumental in maintaining immune 
homeostasis and tolerance in the gut. DCs are virtually 
omnipresent and are remarkably plastic, having the 
ability to adapt to the influences of the microenviron-
ment. Different DC populations with partially overlap-
ping phenotypic and functional properties have been 
described in different anatomical locations. DCs in 
the draining mesenteric lymph nodes, in the intestinal 
lamina propria and in Peyer’s patches partake both in 
the control of intestinal inflammation and in the main-
tenance of gut tolerance. In this respect, gut-resident 
DCs and macrophages exert tolerogenic functions as 
they regularly encounter and sense commensal bac-
teria. In contrast, migrating DC subsets that are re-
cruited to the gut as a result of pathogenic insults initi-
ate immune responses. Importantly, tolerogenic DCs 
act by promoting the differentiation and expansion of 
Treg cells that efficiently modulate gut inflammation, 
as shown both in pre-clinical models of colitis and in 
patients with inflammatory bowel disease (IBD). This 
article reviews the phenotypic and functional features 
of gut DC subsets and discusses the current evidence 
underpinning the DC contribution to the pathogenesis 
of the major clinical subtypes of human IBD. It also 
addresses the potential clinical benefit derived from DC 
targeting either in vivo  or in vitro .
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
The digestive tract has a surface area nearly 200 times 
greater than that of  the skin. Being an important port of  
entry for microorganisms, the gut must be protected by 
effective immune responses. However, immune reactivity 
must be prevented from damaging gut tissues in response 
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to benign foreign material to which the gut is continu-
ously exposed. T cell immunity relies on the recognition 
of  antigenic peptides processed and presented to T cells 
by dendritic cells (DCs), which act as initiators, stimulators 
and regulators of  antigen-specific T cell responses, but 
also play a pivotal role in the maintenance of  tolerance 
towards the commensal microflora[1,2].
DCs are specialized accessory cells distinguishable 
from other mononuclear phagocytes (MPs) such as mono-
cytes and macrophages by their unique morphology and 
ability to capture and process antigens for presentation 
to effector T cells. Upon encounter with pathogens and 
activation, DCs undergo rapid maturation characterized 
by the upregulation of  major histocompatibility complex 
(MHC) and costimulatory molecules and migrate to the 
draining lymph nodes. The remarkable flexibility of  DC 
functions likely results from their ability to sense the 
local environment and to shape the ensuing immune 
response[3,4]. Intestinal MPs are distributed in organized 
lymphoid organs, such as Peyer’s patches (PP) and mes-
enteric lymph nodes (MLN), and are highly abundant in 
the loose connective tissue underlying the epithelium, 
the lamina propria (LP)[5].
It is now established that DCs play a crucial role in 
both immunity and tolerance[1,6]. In a tolerogenic setting, 
DC can induce anergy in antigen-specific T cells or gen-
erate protective FoxP3+ regulatory T cells (Treg) in the 
lymph nodes. Under steady-state conditions, DCs con-
tinuously migrate from peripheral organs via the lymph 
to secondary lymphoid organs, where they present self-
antigens or innocuous environmental antigens to maintain 
peripheral tolerance. The chemokine receptor, CCR7, is 
a key regulator of  the homeostatic and inflammation-in-
duced trafficking of  DCs from skin, lung and gut to their 
respective draining lymph nodes[7].
Human inflammatory bowel disease (IBD) consists 
of  2 dominant disease subtypes, Crohn’s disease (CD), 
largely arising from a Th1 response, and ulcerative coli-
tis (UC), largely mediated by interleukin (IL)-5- and IL-
13-producing T cells or natural killer T cells[8]. The immu-
nopathology of  human IBD relates to an inappropriate 
and exaggerated immune response to constituents of  the 
gut flora in a genetically predisposed individual. Amongst 
other cell types[9], DCs play a role in IBD pathogenesis, as 
suggested by mouse models of  colitis and by observations 
in humans. The local microenvironment regulates the 
function of  mucosal DCs through the presence of  im-
mune cells, non-immune cells and luminal bacteria[10]. In 
principle, DC dysfunction may promote the development 
of  gut inflammation by priming T-cell responses against 
bacteria, by sustaining T cell reactivity within the inflamed 
mucosa and by functioning as effector cells releasing pro-
inflammatory cytokines[11].
DC LINEAGE AND SUBSETS IN MICE 
AND HUMANS
DC origin and precursor-progeny relationships have re-
mained a matter of  controversy and debate for decades[12]. 
Recent landmark studies have led to a better definition of  
DC ontogeny in mice (Figure 1), unraveling that a mac-
rophage and DC precursor (MDP) serves as a common 
bone marrow progenitor for classical or conventional 
DCs (cDCs), plasmacytoid DCs (pDCs) and monocytes 
(Table 1). Specifically, Fogg et al[13] have identified a clo-
nogenic MDP with a CD117+CX3CR1+CD11b-lineage- 
phenotype, representing ~0.5% of  total bone marrow 
cells and giving rise to monocytes, to several macrophage 
subsets and, ultimately, to steady-state CD11c+CD8α+ and 
CD11c+CD8α- DC. Lymphoid organ DCs in the steady      
state originate from a bone marrow precursor with a Lin-
CD115+Flt3+CD117lo phenotype, termed common DC 
progenitor (CDP)[14]. Migratory DC precursors (pre-DCs) 
also exist in the peripheral blood and are in equilibrium 
with DCs in lymphoid organs and in non-lymphoid tissues, 
such as skin, lung, kidney and intestine. DCs actively divide 
in vivo and their lifespan varies from 5 to 7 d in the spleen, 
lymph node, liver and kidney and can be as long as 25 d in 
the lung[15].
DCs lack a unique surface marker, but rather express 
a distinct set of  cell surface antigens. The number of  
DC subsets that have been phenotypically characterized 
and functionally designated is increasing steadily. In ad-
dition to the classical integrin marker CD11c distinguish-
ing DCs, the integrin αE (CD103) recently gained atten-
tion and has been used to sub-classify DC subsets based 
on specific functional activities and anatomic location (see 
below for a thorough discussion)[16]. CD103 mediates 
T cell adhesion to epithelial cells through its binding to 
E-cadherin, which is expressed on the basolateral side of  
epithelial cells but not on endothelial cells. Mice with a 
targeted disruption of  cd103 show a mild reduction in T 
cell numbers in the intraepithelial and LP compartments, 
coupled with the inability to reject islet allografts[17].
MECHANISMS UNDERLYING DC-
MEDIATED TOLERANCE IN THE GUT
One of  the major functions of  tolerogenic DCs may be 
the differentiation of  Treg cells from naïve T cells. Two 
major subtypes of  Treg cells have been described to date, 
namely, naturally occurring CD4+CD25+FoxP3+ Treg cells 
(nTreg) and inducible type 1 Treg cells (Tr1).
DCs as inducers of nTreg cells
Naturally occurring Treg cells, a functionally specialized 
subset of  CD4+ T cells, have been involved in prevent-
ing T cell-mediated and innate immune pathology in a 
number of  disease models[18]. The transcription factor 
FoxP3 is expressed by CD4+CD25+ Treg cells and is fun-
damental for Treg development and function. nTreg cells 
mainly suppress effector T cells through a cell contact-
dependent and largely contact-independent mechanism. 
Membrane-bound transforming growth factor (TGF)-β 
has been implicated in nTreg-mediated inhibition of  T 
cell responses. Moreover, TGF-β1 acts as a co-stimulato-
ry factor for FoxP3 expression, leading to Treg differen-
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tiation from CD4+CD25- T cells. Interestingly, TGF-β1 
production by Treg cells is not required for inhibition of  
colitis, suggesting that Treg cells may induce TGF-β re-
lease by other hematopoietic or stromal cells[19]. Support 
for this hypothesis is provided by the observation that 
suppression of  colitis by TGF-β1-/- Treg cells was inhib-
ited by anti-TGF-β antibodies, indicating that TGF-β is 
central to the function of  Treg cells even when they do 
not synthesize it themselves[19]. In this respect, DCs re-
main a key and intriguing candidate for TGF-β produc-
tion in vivo. It is conceivable that Treg cells be required to 
express TGF-β1 on the cell surface and to present it to 
pathogenic T cells, as previously shown[19].
Treg cells are believed to play a crucial role in inhib-
iting intestinal inflammation and IBD. Notably, Treg 
cells may contribute differentially to the modulation of  
experimental autoimmune gastritis and colitis. Protection 
from colitis, but not from gastric inflammation, has been 
reported to depend on IL-10 expression by CD4+CD25+ 
nTreg cells[20]. The T cell transfer model of  colitis allows 
an understanding of  Treg-mediated mechanisms control-
ling intestinal inflammation. During cure of  experimental 
colitis, Treg cells proliferate and accumulate in MLN 
and colonic LP, in contact with CD11c+ DCs and effec-
tor T cells[21]. Interestingly, IL-10-producing Treg cells 
selectively enrich within the colonic LP, whereas FoxP3-
expressing Treg cells are present in similar frequencies in 
both the secondary lymphoid organs and LP of  colitic 
animals[22]. Transfer of  CD4+CD45RB+ T cells into 
RAG-/- mice causes colitis. Disease development requires 
β7-integrin-dependent intestinal localization. Importantly, 
β7-deficient Treg cells prevent colitis, suggesting that Treg 
accumulation in the intestine is dispensable for disease 
suppression[23]. The presence of  Treg cells impacts on 
CD4+CD45RB+ T cell accumulation in the intestine, indi-
cating that one major function of  Treg cells may involve 
the inhibition of  tissue localization of  Th1 effector cells.
Peripheral blood CD4+CD25high T cells may be de-
creased in active human IBD compared with inactive 
disease[24]. Notably, Treg cells are increased in mucosal 
IBD lesions, coincident with an increase in transcripts 
for IL-8, a hallmark of  inflammation in the gut, and for 
FoxP3[24]. The higher degree of  Treg infiltration in the 
gut LP of  patients with diverticulitis compared with IBD 
suggests that an insufficient increase of  Treg cells in 
IBD accounts for inflammation and intestinal patholo-
gy[24]. In the LP of  human colon, Treg accumulation has 
been detected in a variety of  inflammatory conditions, 
such as diverticulitis, pseudo-membranous colitis and cy-
tomegalovirus-induced colitis, and may not be a specific 
feature of  CD or UC[22]. The presence of  FoxP3+ T cells 
in the LP of  patients with IBD suggests that defects in 
Treg numbers may not account for the pathology, and 
that ineffective Treg activity may rather contribute to 
sustained gut inflammation. 
DCs as inducers of Tr1 cells
Tr1 have been described as a CD4+ T-cell subset releas-
ing high levels of  IL-10, in the absence of  measurable 
IL-2 and IL-4 production, and exerting suppressive func-
tions in an IL-10/TGF-β-dependent but cell contact-
independent manner[25]. The production and release of  
interferon (IFN)-γ and TGF-β by Tr1 cells are compa-
rable with those of  Th0 and Th1 clones, respectively[25]. 






























































Figure 1  Ontogeny of dendritic cell subsets in mice. The most recent evidence elucidating dendritic cell (DC) ontogeny and unraveling the complexity of the 
DC compartment in mice is summarized. The curved arrows in cyan denote proliferation potential. Regulatory T (Treg) cells may contribute to DC development and 
homeostasis in mice, as suggested by studies where Treg depletion has been associated with a 2- and 12-fold increase in precursor conventional DC (pre-cDC) and 
cDC in spleen and lymph node, respectively[14]. MDP: Macrophage and dendritic cell progenitor; CDP: Common dendritic cell progenitor; pDC: Plasmacytoid DC.
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Colitis in the severe combined immunodeficient (SCID) 
mouse model involves the development of  Th1 cells re-
sponding primarily to the intestinal flora. The transfer of  
ovalbumin (OVA)-specific Tr1 cells in SCID mice with 
CD4+CD45RBhi T cell-induced colitis prevents disease 
manifestations, an effect that is dependent upon the in vivo 
activation of  Tr1 cells by feeding mice with OVA[25]. This 
observation indicates that Tr1 cells can inhibit immune 
responses to unknown antigens by a bystander suppres-
sion mechanism. Another report has shown that IL-10-/- 
mice lack CD4+CD45RBlo Treg cells capable of  control-
ling intestinal inflammatory responses, pointing to IL-10 
as a crucial mediator of  tolerance in the gut[26]. Similarly, 
TGF-β is required to suppress Th1-mediated colitis in-
duced by CD4+CD45RBhi T cells[27], indicating that IL-10 
and TGF-β play non-redundant roles in the functioning 
of  intestinal Treg cells.
The source of  IL-10 which regulates colitis remains 
to be unequivocally identified. Treg-derived IL-10 was 
recently shown to be dispensable for suppression of  coli-
tis in Rag1-/- mice, but host IL-10 was required to inhibit 
disease development[28]. Specifically, IL-10 production by 
myeloid CD11b+F4/80+ cells, mostly macrophages, was 
important for the maintenance of  Foxp3 expression by 
Treg cells[28]. IL-10 acted directly on Treg cells, because 
Treg cells lacking IL-10Rβ chain failed to suppress colitis 
when transferred together with CD4+CD45RBhi T cells. 
In addition, this study demonstrates that IL-10 is not re-
quired to maintain FoxP3 expression in non-inflammatory 
conditions, because Treg development and function are 
unaffected in Il10rb-/- mice[28]. It is conceivable that the 
differential requirement for IL-10 for FoxP3 expression 
and maintenance in inflammatory vs non-inflammatory 
conditions may reflect the need for an additional signal to 
counter inflammatory mediators such as IL-6 or tumor 
necrosis factor (TNF)-α[29]. It remains to be determined 
whether IL-10-mediated mechanisms are unique to the 
gut microenvironment or whether IL-10 may be required 
to maintain FoxP3 expression in other organs.
Other studies pointed to Treg-derived IL-10 as a ma-
jor contributor to Treg-mediated suppression[25]. These 
discrepancies may be attributed to differences in the en-
dogenous flora and/or in the model systems studied. Mu-
cosal CD8α+ DCs with a CD11cloB220+ phenotype can 
be isolated from mouse MLN and have been reported to 
promote the suppressive function of  CD4+CD25+ Treg 
cells and to promote the conversion of  naïve T cells into 
Tr1-like cells[30]. At variance with classical Tr1 cells, the 
Tr1-like cells described in this study released IL-10, IL-4 
and IFN-γ and suppressed T helper proliferation[30]. The 
CD8α+ DC were capable of  supporting Tr1-like cell dif-
ferentiation also in the presence of  a maturational stimu-
lus, such as CpG, as reported for other tolerogenic, semi-
mature DC preparations[6,31].
DC expression of indoleamine 2,3-dioxygenase 1 and 
gut tolerance
Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-
catabolizing enzyme implicated in maternal allograft ac-
ceptance and in immune tolerance to tumors[32-36]. IDO1 
converts tryptophan into immune suppressive kynurenines 
that profoundly affect T-cell functions, promoting T-cell 
unresponsiveness, T-cell apoptosis and differentiation 
of  Treg cells. IDO expression has been associated with 
CD103+ DCs in the gut LP and MLN of  mice[37]. Similar-
ly, human intestinal CD11c+CD103+ DCs express higher 
levels of  IDO mRNA compared with CD11c+CD103- 
DCs. IDO inhibition of  mouse CD103+ DCs with the d 
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Table 1  Intestinal dendritic cell subsets and other mononuclear phagocytes described to date
Subset Anatomic location Function, if known Ref.
CD11chiCD11b+CD8α- Peyer’s patches Localized in the subepithelial dome [57]
CD11chiCD11b+CD8α+ Localized in the interfollicular regions [57]
CD11c+CD11b-CD8α- Localized in both subepithelial dome and interfollicular regions; secretion of 
IL-10 in response to CD40 cross-linking; induction of T-cell release of IL-4/IL-10; 
promotion of T-cell proliferation
[58]
CD11cmid plasmacytoid DC
CD11c+CD11b+CD8α+ DC Small-intestinal and colonic 
lamina propria
Low T-cell responses in vitro; IL-12p40lowIL-10+; tolerance to OVA (m); secretion of 
IFN-α; differentiation of Tr1-like cells that secrete IL-10, IL-4 and IFN-γ
[30,55]
CX3CR1+ DC Pro-inflammatory activity dependent upon TNF-α production [101]
CD11chiclass ⅡhiCD103+ DC Generation of CCR9+α4β7+ T cells with gut tropism [51]
CD11b+CD8α-CD103+/- DC
Mesenteric lymph node
Conversion of Foxp3- T cells to Foxp3+ T cells; retinoic acid and TGF-β required [54]
CD11cloB220+CD8α+ Promotion of CD4+CD25+ Treg function; differentiation of Tr1-like cells (IL-10+IL-
4+IFN-γ+) from naïve T cells after repeated stimulations
CD11chiCD11b+CD8α+ See above
CD11chiCD11b-CD8α- See above
CD103+ DC ~50% of CD11c+ DC in the MLN; conversion of naïve T cells into Treg cells; reti-
noic acid and TGF-β required; induction of CCR9 on gut-tropic T cells
[16]
CD103- DC Expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-23p19) and genes such 
as Tbet, tlr2 and tbx21
[16]
CD11chiclass ⅡhiCD103+ DC Induction of CCR9 gut-homing receptor on CD4+ T cells [53]
CD11b+CD11c- macrophages Small and large intestine Induction of Treg cells, secretion of IL-10 but not IL-12p40 or IL-12p70 [105,106]
DC: Dendritic cell; OVA: Ovalbumin; IFN: Interferon; MLN: Mesenteric lymph node; Tr1: Type 1 Treg cells; TGF: Transforming growth factor; IL: Interleu-
kin; M: Mouse studies.
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isomer of  1-methyl-tryptophan (1MT) reduced the ability 
of  IDO+ DCs to convert Treg cells and augmented the 
generation of  IL-17-producing T cells. Mice treated with 
1MT concomitant with adoptive transfer of  OVA trans-
genic T cells and oral immunization with OVA led to a 
reduction in the frequency of  Treg cells in the LP, PP and 
MLN. Ido1-/- mice displayed a decreased percentage of  
Foxp3+ Treg cells in the LP and an almost double the pro-
portion of  IL-17+CD4+ and IFN-γ+CD4+ T cells in the 
intestine compared with wild-type animals. Finally, Rag1-/- 
mice injected with colitogenic T cells from C57BL/6 mice 
experienced more extensive gut inflammation and aggres-
sive disease if  treated with 1MT. Similar effects were dem-
onstrated in mice with dextran sodium sulfate (DSS)-colitis, 
where 1MT administration worsened the mortality rate 
and colon shortening. Collectively, these experiments in-
dicate that IDO may play a previously unappreciated and 
fundamental role in regulating gut inflammation through 
the control of  Th1/Th17/Treg balance.
The expression of  IDO in the murine gut may in-
crease with age via an IFN-γ-dependent mechanism that 
involves commensal microorganisms[38]. IDO-deficient 
mice have abnormally high levels of  both IgG and IgA, 
a phenomenon driven by the commensal flora. IDO 
may then physiologically restrict B-cell responses to 
intestinal commensal bacteria. The elevated levels of  
IgG and IgA in IDO-deficient mice might in principle 
confer resistance to enteric pathogens such as Citrobacter 
rodentium, a gram-negative bacillus similar to human en-
teropathogenic Escherichia coli. When infected orally with 
Citrobacter, IDO-deficient mice appeared well throughout 
the course of  the experiment, at variance with wild-
type animals that had decreased activity, ruffled fur and 
hunched posture, and had attenuated gut colonization by 
the pathogen[39]. IDO-deficient mice had reduced edema, 
inflammatory cell infiltration and epithelial damage in 
colonic tissue sections, associated with lower levels of  
TNF-α compared with wild-type mice. These observa-
tions point to IDO as a novel target to manipulate in-
testinal inflammation and to control diseases caused by 
enteric pathogens.
Crosstalk between DCs and intestinal epithelial cells 
Intestinal epithelial cells (IECs) are a central component 
of  the immune system of  the gut. They express receptors 
for microbial-associated molecular patterns that activate sig-
naling cascades leading to the production of  antimicrobial 
products and chemokines[40]. IECs can also recruit leuko-
cytes to complement their barrier function or to partici-
pate in the activation of  gut adaptive immune responses, 
including the production of  IgA and the differentiation 
of  effector Th1, Th2 and Th17 cells.
IECs are in close contact with LP DCs and have 
been shown to release molecules that influence DC 
functions. Thymic stromal lymphopoietin (TSLP) is a 
cytokine secreted by IECs under steady-state conditions 
and imparts a Th2-polarizing phenotype to DCs[41]. IEC-
derived factors also stimulate the expression of  both 
chains of  TSLP receptor on DCs, namely the common 
IL-7 receptor α chain and the TSLP receptor, thus con-
ferring the ability to respond to TSLP and to drive Th2 
responses. Importantly, TSLP expression by primary 
IECs may be deregulated in a proportion of  patients 
with IBD. The same study also showed that mRNA sig-
nals for TSLP are readily detected in IECs from healthy 
controls, although the protein is consistently below the 
detection limit by immunoprecipitation, unless IECs are 
challenged with bacteria such as S. typhimurium. TSLP 
has been detected in epithelial cells of  the Hassall’s cor-
puscles and activates myeloid CD11c+ DCs in the thymic 
medulla[42]. These apparently mature DCs promote the 
development of  Treg cells through a mechanism that re-
quires peptide-MHC class Ⅱ interactions, and the pres-
ence of  CD80, CD86 and IL-2. Plasmacytoid DCs can be 
also activated by TSLP and become efficient generators of  
Treg cells from thymocytes through an IL-10-dependent 
mechanism[43]. CD4+ T cells triggered through the T cell 
receptor, but not resting CD4+ T cells, respond to TSLP 
with robust proliferation and acquire sensitivity to low 
doses of  IL-2[44].
INTESTINAL DCs UNDER STEADY-STATE 
CONDITIONS AND IN EXPERIMENTAL 
COLITIS
DCs in the non-inflamed gut
Cells with antigen-presenting function within the intes-
tine and associated lymphoid tissue include macrophages, 
conventional CD11c-expressing DCs and plasmacytoid 
DCs. Macrophages belong to a family of  tissue cells that 
includes Kupffer cells in the liver and glial cells in the 
brain and have predominantly innate immune functions, 
such as capturing and killing of  microbes, scavenging 
of  apoptotic and dead cells, and production of  regula-
tory cytokines[45]. Macrophages are the most abundant 
population of  phagocytic cells in the intestine. Distinctive 
characteristics have also been assigned to intestinal mac-
rophages as compared with splenic macrophages or blood 
monocyte-derived macrophages. Early studies identified 
macrophages in the small and large intestine in the mouse, 
based on the expression of  the F4/80 glycoprotein in as-
sociation with CD11b[46]. LP macrophages are detected 
in juxtaposition to CD4+ T cells and in close contact with 
the epithelium[23,47]. CD11b+CD11c- macrophages are 
scattered throughout the villus-tip axis of  small and large 
intestine, express immune regulatory molecules such as 
programmed death ligand 1 (PD-L1) and PD-L2, and 
secrete IL-10 but not IL-12p40 or IL-12p70. They are 
hyporesponsive to Toll-like receptor (TLR) stimulation, 
suppress the differentiation of  Th1 and Th17 cells, and 
promote the differentiation of  Treg cells[23]. Local macro-
phages may contribute to colitis development in IL-10-/- 
mice[48]. The pharmacological depletion of  macrophages 
in this model of  colonic inflammation ameliorated colitis, 
suggesting that IL-10 deficiency impedes the conditioning 
of  macrophages, leading to macrophage-mediated de-
structive inflammatory responses.
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Under steady-state conditions, the functional proper-
ties of  the DC subpopulations vary according to their 
anatomical location. For instance, functional differences 
among DCs from PP, from MLN and from small intes-
tinal and colonic LP have been reported. Within a single 
anatomical site, DCs can de distinguished and further sub-
divided according to their surface membrane phenotype. 
Under inflammatory conditions, DC recruitment to the 
intestine occurs, although it is presently unclear whether 
these DC populations are separate from DCs present in 
the steady-state or whether DCs arriving in the inflamed 
intestinal microenvironment acquire the ability to foster 
pro-inflammatory responses as a result of  their exposure 
to pathogens and local inflammatory mediators.
LP DCs can be isolated in the absence of  overt in-
flammatory stimuli and perform a tolerogenic function 
by constitutively migrating to the draining MLN, where 
they present antigen to T cells. The carriage of  antigens 
from commensal bacterial strains to the MLN might be 
triggered by low-level production of  pro-inflammatory 
cytokines. In this respect, the chemokine receptor CCR9 
is crucial for the positioning of  plasma cells[49] and plas-
macytoid DCs[50] to the small intestine, suggesting that 
the chemokine CCL25/TECK may regulate DC homing 
during inflammatory processes. After their migration to 
the MLN, DCs interact with T and B cells and initiate im-
mune responses aimed at maintaining a non-inflammatory 
state in the intestine. Intestinal DCs have been reported 
to promote the peripheral induction of  FoxP3-expressing 
Treg cells from naïve T cells. Such Treg cells with specific-
ity for commensal bacteria and dietary antigens may pre-
vent naïve T cells from inducing pathological responses, 
thus complementing the pool of  thymus-derived Treg 
cells. In this respect, gut-associated lymphoid tissue DCs 
may synthesize the vitamin A metabolite retinoic acid, that 
selectively induces CCR9 and α4β7 integrin on CD8+ T 
cells with gut tropism[51]. This phenomenon occurs more 
efficiently after oral as compared with intraperitoneal anti-
gen administration, indicating differential DC targeting by 
the 2 immunization routes[51].
CD103 is the α chain of  the αEβ7 integrin expressed 
by most mouse and human intestinal lymphocytes and 
mediating lymphocyte adhesion to E-cadherin-expressing 
intestinal epithelial cells. CD103-expressing DCs may also 
be required to induce gut-tropic effector T cells in the 
MLN[51]. Interestingly, TGF-β plays a dominant role in 
CD103 induction on gut-tropic CD8+ T cells, as shown in 
a mouse model of  post-transplantation graft-versus-host 
disease (GVHD) with T-cell infiltration of  the intestinal 
epithelium[52]. T cells from 2C T cell receptor-Tg mice that 
express a dominant negative TGF-β type Ⅱ receptor were 
incapable of  upregulating CD103 upon migration into 
the intestinal epithelium[52]. In addition, CD103 expres-
sion on host-reactive CD8+ T cells was causally related to 
the development of  GVHD pathology and mortality. Al-
though TGF-β activity is present locally within the intes-
tinal milieu, this study did not exclude the possibility that 
CD8 effectors encounter TGF-β and upregulate CD103 
expression before their entry into the intestinal epithe-
lium. CD103-/- T cells migrate into the host intestine but 
are retained much less efficiently than wild-type T cells, 
indicating that CD103 expression may also contribute to 
T-cell accumulation in the gut[52]. In a T-cell transfer model 
of  colitis, disease-inducing CD4+CD45RBhigh T cells were 
shown to promote colitis development irrespective of  their 
expression of  CD103[53]. However, anti-CD103 antibod-
ies abrogated the suppression of  colitis mediated by Treg 
cells. Further experiments suggested that CD103 expres-
sion by Treg cells was not essential for their function, indi-
cating the requirement for CD103 on non-T host cells for 
protection from colitis[53]. Of  interest, ~50% of  CD11c+ 
DCs in the MLN co-expressed CD103 at high density, at 
variance with ~30% of  splenic DCs. Sorted CD103+ DCs 
activated the proliferation of  allogeneic CD4+ T cells to a 
similar extent compared with the CD103- counterpart but 
were potent inducers of  CCR9 co-expression by day 4 of  
culture, suggesting their ability to impart gut tropism on T 
cells. In addition, CD103+ DCs were inefficient at induc-
ing IL-10 and IFN-γ production by T cells. Collectively, 
this study suggested that DC subsets that are primed in 
the immunosuppressive environment of  the gut may be 
unable to drive the release of  pro-inflammatory cytokines 
such as IFN-γ, thus preventing the development of  un-
wanted effector responses to ingested antigens. Another 
report by the same investigators has shown that CD103+ 
DCs isolated from the MLN may both induce de novo 
expression of  Foxp3 in naïve T cells and maintain pre-
existing Foxp3+ cells[16]. The conversion of  naïve T cells 
into Treg cells by CD103-expressing DCs was completely 
inhibited by anti-TGF-β antibodies, but further enhanced 
by exogenous TGF-β, so that provision of  1 ng/mL 
TGF-β to the T-cell/DC co-cultures translated into the 
expression of  Foxp3 by ~50% of  T cells[16]. Even the 
provision of  high concentrations of  TGF-β to CD103- 
DCs did not allow the generation of  similar percentages 
of  Treg cells to CD103+ DCs, suggesting that CD103- 
DCs may lack an essential cofactor. Further experiments 
led the authors to identify retinoic acid as the cofactor for 
the TGF-β-driven conversion of  Treg cells from naïve 
T cells. Compared with the CD103+ DCs, CD103- DCs 
released higher amounts of  pro-inflammatory cytokines 
(TNF-α, IL-6), and expressed higher levels of  IL-23p19 
and Tbet[16]. Collectively, this study showed the existence 
of  functionally distinct DC populations in the MLN of  
normal mice, with apparent diverging functions. A com-
panion paper by Sun et al[54] has shown, both in a lympho-
penic mouse transfer model and in an immunologically 
complete setting, that retinoic acid released by LP DCs 
promotes Treg conversion in the presence of  TGF-β. 
The LP DCs expressed a CD8α-CD11c+ phenotype and 
displayed the morphologic features of  conventional DCs, 
consisting of  a stellar shape comparable to freshly isolated 
splenic DCs[54].
LP DCs
The extensive phenotypic and functional characterization 
of  mouse LP DCs so far pursued has revealed a greater 
complexity than previously appreciated. The majority of  
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LP DCs express a CD11b+CD8α- phenotype, although 
CD11b-CD8α+ and CD11b-CD8α- DCs have also been 
identified[55]. Treatment of  mice with Flt3 ligand increases 
the proportion of  LP DCs without significantly altering 
the relative proportion of  DC subsets, thus allowing the 
purification of  a higher DC number for detailed func-
tional analyses. Using this approach, some authors have 
shown that LP DCs are not fully mature in situ but they 
can be induced to differentiate in response to appropriate 
stimuli[55]. LP DCs were also less efficient at stimulating 
OVA-specific T-cell proliferation in vitro when compared 
with splenic DCs, and mediated the development of  toler-
ance when transferred to mice fed with OVA[55]. LP DCs 
exhibited a unique cytokine profile, consisting of  low 
levels of  IL-12p40 mRNA associated with constitutive 
IL-10 and type Ⅰ IFN production[55]. A specialized subset 
of  LP DCs with a CD8α+ phenotype has been identi-
fied in mice[30]. Gut-derived CD8α+ DCs secrete IFN-α 
and support antigen-specific suppression mediated by 
CD4+CD25+ Treg cells. Furthermore, CD8α+ DCs favor 
the differentiation of  Tr1-like cells that release high quan-
tities of  IL-10, IL-4 and IFN-γ upon activation with plate-
bound anti-CD3 antibodies[30]. The ability of  CD8α+ DCs 
to induce Tr1-like cells was not affected by their exposure 
to maturation stimuli, as reported for other populations 
of  maturation-resistant, tolerogenic DCs[31].
Other LP DC subsets identified in mice include CD11b-
CD103hi and CD11b+CD103-/low DCs. LP DCs can be 
further subdivided into CD11b-CD103hiCX3CR1- DCs and 
CD11b+ DCs with different CX3CR1 (fractalkine recep-
tor) expression levels[56]. The CD103hiCX3CR1-CD11b- LP 
DCs originate through a DC-committed non-monocytic 
intermediate from MDP, a differentiation pathway that is 
driven by Flt3L. Conversely, CD103-CX3CR1+CD11b+ LP 
DCs derive from Ly6Chi monocytes and their derivation 
involves an extensive, granulocyte-macrophage colony-
stimulating factor (GM-CSF)-driven local expansion in the 
mucosa. Importantly, mice that were persistently or tran-
siently depleted of  LP DCs neither developed spontaneous 
intestinal inflammation nor were susceptible to colitis de-
velopment. In contrast, mice that harbored predominantly 
CD103-CX3CR1+CD11b+ LP DCs developed severe colitis 
in response to a DSS challenge, as evaluated by colonos-
copy and histological examination. This pro-inflammatory 
activity was dependent on TNF-α secretion with ensuing 
epithelial damage, and might also be regulated through 
IL-10/TGF-β production by the CD103hiCX3CR1-CD11b- 
LP DC subset[23]. This study highlighted the importance of  
a critical balance between LP DC subsets for tissue repair 
and gut homeostasis.
PP DCs
PP are the primary sites for the induction of  immune 
responses in the intestinal mucosa and are representative 
of  lymphoid follicles present in diffuse mucosal tissues. 
DCs from PP possess a unique capacity to induce T-cell 
responses that regulate systemic immunity through the 
release of  IL-4 and IL-10 and that provide help for IgA 
B-cell differentiation. It has been shown that PP DCs 
reside in different anatomical sites, with CD11b+CD8α- 
DCs being localized in the subepithelial dome, CD11b-
CD8α+ in the interfollicular regions and CD11b-CD8α- 
[double-negative (DN) DCs] in both compartments[57]. 
The DN DCs constitute approximately 30% of  PP DCs, 
are interspersed within the follicle-associated epithelium, 
with processes extending to the luminal surface, and occa-
sionally associated with M cells within the M-cell pocket[58]. 
DN DCs express intracellular MHC molecules, indicating 
their immaturity, and secrete IL-12p70, suggesting func-
tional similarity to the lymphoid DC subset[58]. Collectively, 
these studies indicate that DN DCs should be able to 
induce Th1 differentiation, at variance with myeloid DC 
subsets that have been implicated in IL-10 release and 
in skewing the immune response towards a Th2 profile. 
It has been proposed that orally delivered antigens may 
initially encounter the myeloid and DN DCs located un-
derneath or within the follicle-associated epithelium. As 
a result of  feeding with low-dose antigen, antigen uptake 
by the DCs would not result in DC activation and migra-
tion but rather in the differentiation of  Th2 or Th3 cells 
with regulatory properties. The T cells interacting with 
antigen would then secrete IFN-γ in the absence of  acti-
vation signals by the DN DCs, thus becoming anergized. 
If  soluble protein antigen is given at high dose, T-cell 
activation would occur in the PP and LP as a result of  DC 
stimulation and migration to the interfollicular regions or 
the MLN. In this scenario, IL-10 produced by the myeloid 
DCs may serve to control detrimental inflammation in-
duced by microbial antigens, whereas DN DCs and lym-
phoid DCs may be acting as the primary source of  IL-12 
for the induction of  Th1 responses[58].
DCs in experimental colitis
The availability of  mice expressing the diphtheria toxin 
receptor under the control of  the Cd11c promoter has 
allowed the selective depletion of  DCs and the study of  
DC role in the development of  intestinal inflammation. 
DC ablation has been correlated with the amelioration 
of  DSS-induced colitis[59]. DSS-stimulated bone marrow-
derived DCs release high quantities of  proinflammatory 
cytokines and chemoattractants in vitro. Furthermore, 
DC adoptive transfer exacerbated disease manifestations, 
whereas DC ablation attenuated disease severity as 
shown by histological examination of  tissue sections. 
However, DC activation with TLR9 ligands before colitis 
induction with DSS exacerbated disease manifestations. 
Since DSS injures the colonic epithelium, it is conceiv-
able that, at least in this model, DCs exerted protective 
effects through stimulating repair of  colonic epithelial 
cell layers rather than modulating the immune response.
There is evidence that DCs may play both protec-
tive and detrimental roles in intestinal pathology. In DSS 
colitis, an experimental model resembling acute colitis, 
DC ablation during DSS administration ameliorated 
disease manifestations[60]. Conversely, colitis was exacer-
bated if  DCs were ablated before DSS treatment, sug-
gesting that DCs are protective in initial phases of  colitis 
but play a pathogenic role during the disease course[60].
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CD83 and is located in the T-cell areas in both the colonic 
lymphoid follicles and the MLN. In contrast, pDCs were 
hardly detected in the colon and MLN. The fraction of  
circulating DC precursors has been found to correlate with 
established IBD activity indices[68]. Specifically, higher per-
centages of  pDC and myeloid DCs were measured during 
disease remission compared with acute flares, suggesting 
DC migration to secondary lymphoid organs. In line with 
this hypothesis, DC precursors from patients with IBD 
expressed α4β7, a gut-homing integrin marker and receptor 
for MAdCAM-1 also detected on LP T cells[69]. Important-
ly, immature DCs are significantly reduced in active IBD, 
indicating that potentially tolerogenic DC subsets may be 
defective during disease reactivation.
M-DC8+ DCs have been detected in the subepithelial 
dome of  ileal PP from 3 patients with untreated CD[70]. In 
one of  these patients, an ileal biopsy performed 6 mo af-
ter glucocorticoid-induced clinical remission documented 
the complete disappearance of  M-DC8+ DCs from the 
ileal mucosa. The observation that M-DC8+ DCs secrete 
large amounts of  TNF-α but not IL-10 upon stimula-
tion with lipopolysaccharide (LPS) suggests that these cell 
types might contribute to the pathogenesis of  IBD[70].
Colonic CD11c+ DCs from patients with either CD or 
UC express higher levels of  TLR2 (interacting with pepti-
doglycan and bacterial lipoproteins), TLR4 (a receptor for 
LPS) and CD40 compared with non-inflamed CD tissues 
and tissues from healthy controls[71]. This may lead to en-
hanced recognition of  bacterial products and an increased 
response to them. Importantly, treatment with TNF-α 
blocking antibodies translated into the downregulation of  
CD40 expression on DCs, irrespective of  resolution of  
inflammation at the tissue level. Also, production of  IL-6 
and IL-12 at the single-cell level was increased in DCs 
from patients with CD but not with UC compared with 
healthy controls.
Although the DC abnormalities documented in UC 
generally resemble those evidenced in CD, differences 
may exist when comparing these 2 major forms of  IBD. 
Epstein-Barr virus-induced gene 3 (EBI3) encodes a se-
creted protein that shares 27% amino acid sequence iden-
tity with IL-12p40. EBI3 can substitute for p40 to form 
a heterodimer with IL-12p35, and is an IL-27 subunit[72]. 
EBI3 expression is upregulated by macrophage/DC-like 
cells within the LP of  patients with active UC but not 
CD[73]. These data are consistent with a scenario in which 
EBI3 opposes the IL-12p40/p35 heterodimer and down-
regulates the cytotoxicity promoted by IL-12. In addition, 
this study reinforced the view that macrophages and DCs 
serve more than one role in the pathogenesis of  IBD, be-
ing either protective or detrimental.
DCs AS TOOLS AND TARGETS FOR 
THERAPY IN IBD
Different approaches have been proposed to restore and/
or enhance the tolerogenic properties of  DCs, including 
in vitro treatment with growth factors and use of  drugs 
that target DC number and/or function (Figure 2)[74,75].
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In a T-cell transfer model of  colitis induced by CD45R-
BhiCD4+ T cells, transplanted T cells formed aggregates with 
sub-epithelial CD11c+ DCs in the MLN[61]. Blocking OX40-
OX40L interactions prevented the development of  colitis. 
DC activation via CD40 has been reported to cause colitis 
in the absence of  T and B cells and through a cytokine-
dependent mechanism[62].
Intestinal inflammation is correlated with significant 
changes in the cellular composition of  the colonic LP. Gut 
inflammation in mice is accompanied by a marked infiltra-
tion of  CD11c+ DCs within the LP[63]. From a phenotypic 
standpoint, these DCs express high levels of  CD80 and re-
semble mature activated DCs, while secreting low levels of  
IL-10 and IFN-α. Of  interest, CD103+ DCs were dramati-
cally reduced in the LP of  colitic mice but were detectable 
in the spleen, suggesting that intestinal CD103+ DCs may 
migrate to lymphoid organs during inflammation.
The observation that IL-10-deficient and TGF-β-
deficient mice develop spontaneous colitis point to IL-10 
and TGF-β as important determinants of  DC function 
in the gut. In a T-cell transfer model of  colitis, Treg pro-
duction of  IL-10 was dispensable for disease suppres-
sion but IL-10 secreted by LP CD11b+ macrophages was 
crucial to maintain FoxP3 expression in Treg cells[28]. It 
is conceivable that intestinal bacteria are a fundamental 
trigger of  IL-10 production by LP macrophages through 
the activation of  TLR signaling. It is presently unknown 
whether IL-10 signals are also required to maintain FoxP3 
expression in Treg cells from other organs during inflam-
mation[29]. Serum IL-10 is reportedly normal in patients 
with IBD[64]. However, LP mononuclear cells are im-
paired in the ability to release and respond to IL-10[64], 
suggesting that IL-10 provision might be beneficial in 
human IBD through effects on the DC compartment[65].
DCs IN HUMAN IBD
DCs accumulate at sites of  inflammation in patients with 
IBD, whereas both myeloid DC and pDC populations are 
depleted in the peripheral blood of  patients with active 
disease. DC recruitment to the gut may be the result of  an 
increased expression of  chemokines such as CCL20 or of  
addressins, such as mucosal vascular addressin cell adhe-
sion molecule-1 (MAdCAM-1). CCL20 is a nuclear factor-
κB-regulated molecule that mediates the CCR6-dependent 
recruitment of  DCs and T cells to mucosal surfaces. 
CCL20 has been detected at increased levels in the muco-
sal epithelium covering lymphoid follicles in patients with 
both types of  IBD, in proximity to CCR6-expressing cell 
types, such as langerin+ DC, B cells and memory T cells[66]. 
Phenotypically heterogeneous populations of  DCs have 
been identified in colonic tissues and MLN from patients 
with IBD[67]. One population consists of  immature DCs 
expressing DC-specific intercellular adhesion molecule-
grabbing non-integrin (SIGN) and mainly located at 
antigen-capturing sites in the mucosa and medullary 
cords. A second population expresses CD141 and has a 
similar localization as that of  DC-SIGN+ DCs. The third 
DC subset consists of  mature DCs expressing S-100 and 
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and IL-10 production, being reversed by in vivo blocking 
of  these cytokines. This elegant study suggests that in 
vitro conditioning of  DC preparations with VIP and self-
antigens might be pursued as therapeutic strategy in colitis 
and possibly other inflammatory disorders[77,78], also to 
minimize patients’ dependence on non-specific immune 
suppressive drugs currently in use for human IBD.
TGF-β1 gene-modified immature DCs with enhanced 
tolerogenicity undergo efficient transport to inflamed 
colonic tissues and delay the progression of  murine IBD 
induced by DSS[79]. DC injections in mice with established 
colitis alleviated weight loss and reduced intestinal bleed-
ing, translating into a lower disease activity index compared 
with control DC or untreated mice. DC vaccination was 
associated with increased Treg numbers in the MLN and 
with increased TGF-β1 levels in mouse colon tissues[79].
Probiotic bacteria
Probiotics, mainly belonging to the lactic acid bacteria 
(LAB) family, exert beneficial effects in human or animal 
health and are presently considered as peace-keepers in 
the gut[40,80]. The regular intake of  probiotic bacteria may 
contribute to immune homeostasis by altering microbial 
balance or by interacting with intestinal immune cells. 
Dysbiosis, namely, an imbalance between pro-inflamma-
tory and anti-inflammatory bacteria in favor of  the for-
mer, may have a causative role in patients with IBD. Pro-
biotics have been tested both in animal models of  colitis 
and in patients with IBD. The potential mechanisms of  
action of  probiotic bacteria include their interaction with 
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Adoptive transfer of cytokine-modulated DCs
DCs have been targeted in animal models of  intestinal 
inflammation. Regulatory DCs differentiated with vasoac-
tive intestinal peptide (VIP) and GM-CSF (DC-VIP) have 
been transferred to BALB/c mice with colitis induced by 
trinitrobenzene sulfonic acid (TNBS), a Th1-mediated 
disease requiring T-cell activation with subsequent macro-
phage recruitment and activation[76]. Mice received the DC 
preparations either 8 h after TNBS instillation or 6 d after 
colitis induction in order to assess their therapeutic effects 
both on colitis induction and on established disease. DC 
infusion ameliorated disease severity and histopathology, 
being associated with inhibited Th1 responses and with 
the in vivo differentiation of  IL-10-producing Treg cells. 
DC-VIP decreased the production of  proinflammatory 
cytokines both systemically and locally, and deactivated 
spleen macrophages, blunting the in vitro production of  
TNF-α and IL-12 in response to LPS challenge. Impor-
tantly, DC-VIP augmented the number of  TGF-β/IL-
10-secreting CD4+ T cells within LP mononuclear cells 
cultured in the presence of  colonic proteins extracted 
from colitic mice. Also, CD4+ T cells obtained by the 
MLN of  DC-treated mice suppressed proliferation and 
IL-2 production by autoreactive CD4+ T cells in response 
to colonic proteins. These CD4+ T cells were also capable 
of  reversing the body weight loss which is characteristic 
of  TNBS-induced colitis when transferred to colitic mice, 
suggesting the acquisition of  a potent regulatory activity 
after their in vivo encounter with DC-VIP. Finally, the ther-
apeutic effect of  CD4+ T cells was dependent on TGF-β 
DC vaccination

















Figure 2  Potential strategies to modulate dendritic cell functionality in human inflammatory bowel disease. In vitro differentiated tolerogenic dendritic cell 
(DC) have been administered to mice with inflammatory/autoimmune disorders. Vasoactive intestinal peptide (VIP) has a unique ability to skew DC function towards 
a tolerogenic profile and has been used to vaccinate animals with colitis, rheumatoid arthritis and post-transplantation graft-versus-host disease[76,77]. Selected growth 
factors have shown to modulate immune reactivity in vivo. For instance, granulocyte colony-stimulating factor (G-CSF) has been successfully given to patients with 
Crohn’s disease, leading to accumulation of pDC in the lamina propria and increase in IL-10 production, with favorable repercussions on disease manifestations[89]. 
GM-CSF: Granulocyte-macrophage colony-stimulating factor; IL: Interleukin; TNF: Tumor necrosis factor.
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TLR and DCs in the gut. The demonstration of  anti-
inflammatory effects after systemic administration of  
probiotics suggests that regulatory cell populations may 
be induced distant from the site of  inflammation[81].
Importantly, probiotics may present strain-specific 
in vitro immune modulating actions, that are strictly cor-
related with their in vivo anti-inflammatory effects. For 
instance, L. salivarius Ls33 and L. rhamnosus Lr32 possess 
high immunoregulatory capacities and efficiently protect 
from murine TNBS-induced colitis, at variance with other 
strains such as L. acidophilus NCFM and L. lactis MG1363 
that exhibit an opposite immunological profile[82]. The 
protective effect of  probiotic-treated DCs was attributed 
to a downregulation of  proinflammatory mediators such 
as IL-12 and IL-17, paralleled with an acute overexpres-
sion of  IFN-γ and IDO[82]. Of  interest, pre-formed natu-
rally occurring Treg cells were required for the protective 
effect of  probiotic-treated DCs, as shown by experiments 
with an anti-CD25 rat monoclonal antibody.
The probiotic mixture designated IRT5 contains 5 dif-
ferent probiotic strains. IRT5 has been shown to induce 
T-cell and B-cell hyporesponsiveness when administered 
for 20 d to mice by the oral route[83]. Even more intrigu-
ingly, IRT5 increased FoxP3 expression in MLN as a result 
of  the enhanced conversion of  naïve T cells into Treg 
cells and the augmentation of  the suppression function of  
pre-existing natural Treg cells. These effects were medi-
ated through the promotion of  DC tolerogenic activity, 
with high expression of  IL-10, TGF-β, IDO and COX-2 
mRNA. IRT5 retarded the progression of  TNBS-induced 
colitis and was also efficacious in other immune-mediated 
disorders, such as atopic dermatitis and collagen-induced 
arthritis. Both the atopic ear and the inflamed colon of  
IRT5-treated mice were enriched with FoxP3-expressing 
Treg cells, likely as a result of  increased tissue levels of  
CCL1 and CCL22, chemokines involved in Treg attraction.
The probiotic mixture VSL#3, which contains 8 dif-
ferent bacterial strains and is clinically beneficial in human 
IBD and pouchitis, has been reported to downregulate 
IL-12 and upregulate IL-10 production by human blood 
and colonic LP DCs in a dose-dependent fashion[84]. This 
change in DC functional polarization translated into the 
inhibition of  in vitro generation of  Th1 cells from alloge-
neic CD4+ T cells.
A comprehensive analysis of  previously published 
studies detailing the activity of  different probiotics in 
animal models of  colitis suggests that the colitis model 
used may affect the results[85]. An interesting study has 
evaluated the ability of  3 Lactobacilli strains (plantarum, 
LGG and paracasei B21060) to activate DCs either direct-
ly or indirectly through epithelial cells. While inducing 
similar degrees of  DC phenotypic maturation, the dif-
ferent strains elicited differential cytokine release, with L. 
paracasei inducing lower levels of  IL-12p70, TNF-α and 
IL-10. The lactobacilli also affected epithelial cell func-
tion, and supernatants of  L. paracasei-treated epithelial 
cells drastically reduced the ability of  DCs to activate T 
cells and drive their polarization towards a Th1 pheno-
type. Finally, the in vitro activity of  probiotics was predic-
tive of  their in vivo efficacy in an acute model of  colitis. 
Taken together, these studies indicate that probiotics 
interact both with immune cells and with non-immune 
cells and that the clinical use of  individual bacterial 
strains should be proposed and recommended only after 
taking into account in vitro immunostimulatory or immu-
noregulatory activity.
Immune modulating drugs
Granulocyte-CSF (G-CSF) has remarkable immune 
modulating activities[86]. Indeed, G-CSF mobilizes DC2, 
differentiates tolerogenic DCs in vitro through IL-10 and 
IFN-α, and polarizes naïve T cells to a Tr1-like functional 
profile[31,87,88]. G-CSF has been administered to patients 
with CD in order to modulate immune reactivity and in-
duce potential clinical benefit[89]. Nine patients with active 
CD received subcutaneous G-CSF for 28 d at 5 μg/kg 
of  body weight. Six patients reported improvement in 
the CD activity index (CDAI) and achieved either a clini-
cal response (4 patients) or remission (2 patients). The 
3 non-responding patients had a longer duration of  dis-
ease, had had bowel resections and one was the only CD 
patient with active fistulae. In responder patients, IL-10 
production by isolated memory CD4+ T cells was signifi-
cantly higher at the end of  G-CSF treatment compared 
with non-responders. Conversely, IFN-γ production in 
post-G-CSF peripheral blood samples was significantly 
higher in non-responders. G-CSF also affected the rela-
tive proportion of  circulating myeloid DCs and pDCs, 
inducing a decrease in the myeloid DC-to-pDC ratio in 
responding patients. Notably, 4 patients in the responder 
group showed an increase in LP CD123+ DCs[89]. In sharp 
contrast, accumulation of  CD123+ pDCs could not be 
evidenced in the LP of  non-responders. Finally, the per-
centage of  FoxP3-expressing cells within LP CD25+ cells 
decreased significantly in non-responders at the end of  
treatment. In line with this, the fraction of  CD25hiFoxP3+ 
cells increased in the LP of  responding patients at the end 
of  treatment, although these differences failed to achieve 
statistical significance. Collectively, this study provided 
proof-of-principle in favor of  IL-10-mediated immune 
regulation by G-CSF in patients with IBD and suggested 
that treatment with this cytokine may translate into disease 
control. G-CSF at 3 μg/kg of  body weight was also highly 
effective at controlling an UC-like syndrome in a 23-year-
old patient with glycogen storage disease Ib[90]. G-CSF 
therapy was maintained for 16 years, with good control of  
gastrointestinal symptoms and dramatic improvement of  
colon histology.
There is evidence that TNF-α antagonism translates 
into changes in DC function. Although this has been 
primarily shown in patients with rheumatoid arthritis, 
it is likely that modifications of  DC functions by TNF 
blockers may also impact on the clinical manifestations 
of  IBD. Both etanercept and adalimumab were shown 
to downregulate CD83, CD80 and CD86 expression on 
monocyte-derived DCs and to reduce their T-cell stimula-
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tory capacity[91]. Anti-TNF-treated DCs polarize T-cell 
responses in vitro and favor T-cell release of  IL-10, IL-4 
and IL-17. Although no correlation was found between 
the clinical response to TNF blockade and the functional 
modulation of  DCs in vitro, DCs derived from patients 
with rheumatoid arthritis given TNF blocking agents en-
hanced T-cell production of  IL-10, while decreasing the 
release of  IL-4, IL-17 and IFN-γ. Infliximab may also 
suppress the antigen-presenting capacity of  DCs derived 
from patients with psoriasis by reducing the expression of  
CD1a and costimulatory molecules, an effect that is not 
reversed by LPS[92].
Mesenchymal stromal cells 
Mesenchymal stromal cells (MSC) are cells endowed with 
multi-lineage differentiation capacity and have been iso-
lated from bone marrow, adipose tissue, amniotic fluid, 
placenta and umbilical cord blood. MSC affect both in-
nate and adaptive immune responses and have reduced 
immunogenicity, thus being a promising therapeutic tool 
for inflammatory, autoimmune and degenerative dis-
eases[93]. Adipose tissue-derived MSC have been shown 
to ameliorate experimental colitis through the promotion 
of  IL-10 release with subsequent inhibition of  activated 
macrophages and differentiation of  Treg cells[94]. Impor-
tantly, the intrafistular injection of  in vitro-expanded MSC 
(median number: 64 × 106 for each patient) has resulted 
into sustained complete closure of  fistula tracks, reduction 
of  perianal disease activity index, and with rectal mucosal 
healing in 10 patients with CD[95]. Intriguingly, the per-
centage of  mucosal and circulating Treg cells significantly 
increased during treatment and remained stable until com-
pletion of  the 12-mo follow-up period. T cells isolated 
from the inflamed mucosal areas released higher amounts 
of  IL-10 when co-cultured with MSC in vitro. Based on 
previously published data on the ability of  IL-10 to skew 
DC differentiation towards a tolerogenic profile[96,97], it is 
tempting to speculate that MSC therapy may target pro-
inflammatory DCs in vivo, through the promotion of  
IL-10 release by colitogenic T cells.
Based on the experience reported in patients with 
GVHD[98], MSC have also been infused intravenously, 
at a dose of  1-2 × 106 cells/kg of  body weight, in 10 
patients with chronic active CD, refractory to all cur-
rently available medical therapeutic options[99]. Although 
MSC-based therapy did not induce clinical remissions 
as defined by a CDAI < 150, reductions of  70 points in 
CDAI were recorded in 3 patients. The biological effects 
of  MSC intravenous infusion included a trend towards 
higher percentages of  CD4+CD127+ bona fide Treg cells. 
In vitro, patient-derived MSC inhibited the proliferation 
of  autologous peripheral blood mononuclear cells and 
decreased their production of  TNF-α. Collectively, the 
studies published so far demonstrate that MSC from pa-
tients with CD can be expanded in vitro and may induce 
favorable therapeutic effects in vivo, including differentia-
tion of  Treg cells, and possibly functional inhibition of  
DCs within the inflamed gut.
CONCLUSION
It is now clear that DC activation is a contributing factor 
in generation of  IBD, as indicated both by mouse models 
of  gut inflammation and by human disease. The recent 
advances in the phenotypic and functional characterization 
of  DC populations in humans have unveiled a remarkable 
and previously unappreciated heterogeneity within the DC 
compartment but have also led to the identification of  
potential targets for therapeutic manipulation. A thorough 
understanding and knowledge of  DC subsets and func-
tionality in humans is a prerequisite for delivering inter-
ventions aimed at correcting DC malfunctioning. Several 
other cell types with APC function cooperate to ensure 
appropriate immune responses in the gut. They include 
IEC, basophils, MSC and other non-immune cells[10,41]. 
Theoretical strategies to interfere with DC activity include 
vaccination with gene-modified DCs or cytokine-treated 
DCs to restore tolerance, growth factor administration, 
therapy with DC-modulating drugs, and use of  probiotics. 
The impact of  TNF blocking antibodies on DC functions 
needs to be further investigated. Some of  these approach-
es have been successfully applied to animal models of  
gut inflammation and other autoimmune/inflammatory 
disorders such as multiple sclerosis and arthritis. In this re-
spect, “tolerogenic vaccination” with cytokine-modulated 
DCs may hold promise for the treatment of  intestinal 
inflammation. However, there is a theoretical concern that 
tolerogenic DCs suppress beneficial anti-infective and 
anti-tumor responses, in addition to unwanted immune 
reactivity. These issues must be carefully addressed before 
this approach is translated into the clinic. Studies in mu-
rine GVHD are somehow reassuring, having clearly indi-
cated that the injection of  cytokine-treated DCs preserves 
CD8+-mediated cytotoxic responses against leukemia 
while blunting GVH reactivity[100,101]. Finally, the patient 
categories that may benefit from DC-based therapeutic 
approaches need to be identified. It should be emphasized 
that other cell-based interventions such as the intravenous 
infusion of  MSC have not induced any clinical remission 
in severe refractory CD[99]. Conceivably, patients with IBD 
should be offered DC-centered treatments earlier in the 
disease course, following patient profiling and stratifica-
tion on the basis of  molecular predictors for complicated 
disease (genetic markers such as NOD2 homozygous or 
compound heterozygous, and anti-microbial antibodies) 
as well as clinical features at diagnosis[102]. There is evi-
dence from both pediatric and adult IBD that treatment 
of  short-duration CD with TNF antagonists is associated 
with better response and remission rates[103,104]. Whether 
DC-based approaches have the potential to slow disease 
progression and alter the natural history of  IBD will 
hopefully be determined in the near future.
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